Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Public ClinicalTrials.gov record NCT04553692. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multicenter, Phase 1a/1b Study of Aplitibart (IGM-8444) As a Single Agent and in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of aplitabart+FOLFIRI+bevacizumab.
Study identification
- NCT ID
- NCT04553692
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Interventions
- Aplitabart (IGM-8444) Drug
- FOLFIRI Drug
- Bevacizumab (and approved biosimilars) Drug
- Birinapant Drug
- Venetoclax Drug
- Gemcitabine Drug
- Docetaxel Drug
- Azacitidine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2020 (Actual)
- Primary completion
- Jan 20, 2025 (Actual)
- Completion
- Jan 20, 2025 (Actual)
- Last update posted
- Mar 28, 2025
2020 – 2025
United States locations
- U.S. sites
- 37
- U.S. states
- 19
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Cancer and Blood Specialty Clinic (CBSC) | Los Alamitos | California | 90720 | — |
| USC Norris | Los Angeles | California | 90033 | — |
| UCLA | Los Angeles | California | 90404 | — |
| UC Irvine Manchester Pavilion | Orange | California | 92868 | — |
| UCSF | San Francisco | California | 94143 | — |
| Rocky Mountain Cancer Centers | Denver | Colorado | 80218 | — |
| SCRI at Healthone | Denver | Colorado | 80218 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| FL Cancer Specialists - Lake Mary | Lake Mary | Florida | 32746 | — |
| Memorial Cancer Institute | Pembroke Pines | Florida | 33028 | — |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46804 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40241 | — |
| Ochsner Cancer | Jefferson | Louisiana | 70121 | — |
| Maryland Oncology Hematology, PA - Columbia | Columbia | Maryland | 21044 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Minnesota Oncology - Minneapolis Clinic | Minneapolis | Minnesota | 55404 | — |
| Mayo Clinic | Minneapolis | Minnesota | 55905 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Gabrail Cancer Research | Canton | Ohio | 44718 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| SCRI - Tennessee | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Austin | Austin | Texas | 78705 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
| US Oncology - Dallas | Dallas | Texas | 75246 | — |
| US Oncology- Texas Oncology - Fort Worth | Fort Worth | Texas | 76104 | — |
| The University of Texas, MD Anderson | Houston | Texas | 77030 | — |
| Texas Oncology - San Antonio Northeast | San Antonio | Texas | 78217 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| Inova Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| US Oncology- Virginia Oncology - Norfolk | Norfolk | Virginia | 23502 | — |
| Seattle Cancer Alliance - Fred Hutch | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04553692, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 28, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04553692 live on ClinicalTrials.gov.